Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11831250 | 0.78 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL7116908 | 0.77 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL5973140 | 0.77 | GABRA1 (0.45) | GABRA1GABRB2GABRB1 | |
| SCHEMBL7124022 | 0.76 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL19640310 | 0.75 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL15122382 | 0.74 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL18469082 | 0.72 | GABRA1 (0.62) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL3844252 | 0.71 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL5257484 | 0.70 | CYP1A2 (0.38) | CA1CA2CYP1A2CYP3A4TSHR | |
| SCHEMBL9162164 | 0.70 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | GABRA1 3433/4885GABRG2 3050/4885GABRB3 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.